Sejima et al emphasized the concept of “Fas ligand tumor counter‐attack,” where FasL in tumor cells induce apoptosis of cytotoxic T lymphocytes in the tumor microenvironment, thus higher NLR. The gene discussed is FASLG; the disease is neoplasm.